Medical Education Materials Sample Clauses

Medical Education Materials. Evelo will prepare and produce all Medical Education Materials for use in the Territory and will provide English-language proof copies of initial versions of all Medical Education Materials for use in the Territory and all substantive updates to such Medical Education Materials to the PCC to review, discuss, and determine whether to approve. In addition, ALJ may propose new or modified Medical Education Materials for use in the Territory at any time and submit such materials to the PCC to review, discuss, and determine whether to approve. ALJ will not use Medical Education Materials that have not been approved by the PCC, including any presentation by any key opinion leaders in the Territory (unless otherwise approved in writing by Evelo). All Medical Education Materials will be compliant with Applicable Laws and the Medical Affairs Plan. In addition, to the extent permitted under Applicable Laws within the Territory, and to the extent bearing any Housemarks, the Medical Education Materials to be distributed in such countries by each Party’s respective medical affairs personnel will include the Evelo Housemarks and the ALJ Housemarks with equal prominence. Each Party will provide to the other Party proof copies of the Evelo Housemarks and ALJ Housemarks (as applicable) to be included in connection with all cobranding described in this Section 7.3 (Medical Education Materials) in the manner and format as may be reasonably specified by a Party from time-to-time. Each Party will, directly or through its Affiliates, have full responsibility for the dissemination of all applicable Medical Education Materials to its medical affairs personnel and other representatives who need such materials to perform such Party’s Medical Affairs under this Agreement or the Medical Affairs Plan.
Sample 1
AutoNDA by SimpleDocs
Medical Education Materials. All written medical educational materials to be provided to healthcare professionals relating to any condition treated with the Product, and other media and materials used to educate the public regarding the Product or any indication treated with the Product (collectively and including translations, “Medical Education Materials”) will be prepared by Pfizer for use in the Pfizer Commercialization Territory and by BioNTech for use in the BioNTech Commercialization Territory. Subject to applicable Law, Pfizer will determine the content, quantity and method of distribution of all such Medical Education Materials and other Pfizer Commercial Materials for use in the Pfizer Commercialization Territory in its sole discretion and BioNTech will determine the content, quantity and method of distribution of all such Medical Education Materials and other BioNTech Commercial Materials for use in the BioNTech Commercialization Territory in its sole discretion, provided that, in each case, all such Medical Education Materials and Pfizer Commercial Materials or BioNTech Commercial Materials, as applicable, will be in compliance with applicable Law. Pfizer and BioNTech each will provide the other copies of the Medical Education Materials it prepares, and the other Party shall be free to utilize all or part of such Medical Education Materials in the design of the Medical Education Materials it will prepare solely for use in and distribute solely by its or its Affiliates’ MSLs and other employees, as permitted by applicable Law and such Party's Internal Compliance Codes, in its Commercialization Territory. Each of Pfizer and BioNTech will, and will cause its respective Affiliates and its and their respective Representatives, including each MSL and other Representative to, as applicable, (a) use all Pfizer Commercial Materials solely in connection with Pfizer’s MSL Activities under this Agreement, (b) use all BioNTech Commercial Materials solely in connection with BioNTech’s MSL Activities under this Agreement, (c) not create or modify, distribute or use sales, promotion or any other material relating to the Product other than the Medical Education Materials or other approved materials per each respective Party’s Compliance policies, and requirements under local labeling, Regulatory Approval and applicable Law.
Sample 1
Medical Education Materials. Apellis shall be responsible for preparing, producing, and disseminating all Medical Education Materials for use in the Apellis Territory. Sobi shall be responsible for preparing and producing all Medical Education Materials for use in the Sobi Territory. Each Party shall submit copies of initial versions of, and any material updates to, the material Medical Education Materials for which it is responsible (excluding translations of Medical Education Materials that have been previously provided to the JMC) to the JMC. Each Party shall ensure that all Medical Education Materials used by or on behalf of such Party for any Product are compliant with Applicable Laws and materially consistent with the Medical Affairs Strategy.
Sample 1
Medical Education Materials. One Party, as determined per the Annual Commercialization Plan and Budget, shall prepare all Medical Education Materials used in a given year in connection with Final Product in Japan, under the direction of the JJCC; provided, that all such materials shall be reviewed and approved by BMKK’s and MJ’s medical, regulatory and legal teams, and reviewed and approved by the JJCC prior to use by either such Party.
Sample 1

Related to Medical Education Materials

  • Training State Street agrees to provide training, at a designated State Street training facility or at the Designated Locations, to the Fund’s personnel in connection with the use of the System on the Designated Configuration. The Fund agrees that it will set aside, during regular business hours or at other times agreed upon by both parties, sufficient time to enable all operators of the System and the Data Access Services, designated by the Fund, to receive the training offered by State Street pursuant to this Addendum.

  • Training and Education (i) The parties shall work together to develop and implement a training program for client services and the sales and marketing representatives of each party to ensure that a clear and consistent message is delivered to all prospective customers. Following such implementation, each party agrees to train its client services and sales and marketing representatives in accordance with such training program.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Clinical Data and Regulatory Compliance The preclinical tests and clinical trials conducted by the Company, and to the knowledge of the Company, the preclinical tests and clinical trials conducted on behalf of or sponsored by the Company, that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such studies and with standard medical and scientific research procedures and all applicable laws and regulations, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, and 312; each description of the results of such studies is accurate and complete in all material respects and fairly presents the data derived from such studies, and the Company and its subsidiaries have no knowledge of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; the Company and its subsidiaries have made all such filings and obtained all such Permits as may be required by the Food and Drug Administration of the U.S. Department of Health and Human Services or any committee thereof or from any other U.S. or foreign government or drug or medical device regulatory agency, or health care facility Institutional Review Board (collectively, the “Regulatory Agencies”) for the operation of the Company’s business as currently conducted, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor any of its subsidiaries has received any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or modification of any clinical trials that are described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus; and the Company and its subsidiaries have each operated and currently are in compliance in all material respects with all applicable rules and regulations of the Regulatory Agencies except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  • Medical Examination The Executive shall be reimbursed by the Company for the reasonable cost of one annual medical examination upon presentation of an expense statement.

  • Commercialization Reports After the First Commercial Sale of a Licensed Product anywhere in the Territory, LICENSEE shall submit to Cornell semi-annual reports on or before each February 28 and August 31 of each year. Each report shall cover LICENSEE’s (and each Affiliate’s and Sublicensee’s) most recently completed calendar half-year and shall show:

  • Investment Advice and Research Services If and to the extent requested by the Sub-Advisor, the U.K. Sub-Advisor shall provide investment advice and research services to the Sub-Advisor with respect to all or a portion of the investments of each Portfolio. In connection with providing such investment advice and research services, the U.K. Sub-Advisor shall furnish to the Sub-Advisor on behalf of each Portfolio such factual information, research reports and investment recommendations as the Advisor may reasonably require. Such information may include written and oral reports and analyses.

  • Clinical Data The descriptions of the results of any studies and tests conducted by or on behalf of, or sponsored by, the Company or its subsidiaries, or in which the Company has participated, that are described in the Disclosure Package and the Prospectus, or the results of which are referred to in the Disclosure Package and the Prospectus do not contain any misstatement of material fact or omit to state a material fact necessary to make such statements not misleading. The Company has no knowledge of any studies or tests not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Disclosure Package or Prospectus.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • TECHNICAL SUPPORT SERVICES 2.1 The technical support services (the "Services"): Party A agrees to provide to Party B the relevant services requested by Party B, which are specified in Exhibit 1 attached hereto ("Exhibit 1").

Time is Money Join Law Insider Premium to draft better contracts faster.